| Expression of Urokinase-Type Plasminogen Activator (uPA), its Receptor (uPAR), and Inhibitor (PAI-1) in Human Breast Carcinomas and Their Clinical Relevance. | |
| | |
MedLine Citation:
|
PMID: 22467324 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Serine proteases convert plasminogen to plasmin which is involved in tissue remodeling under physiologic and pathophysiologic conditions, including breast carcinoma invasion and progression. Both urokinase-type plasminogen activator (uPA) and pro-uPA associate with uPA receptor (uPAR) on target cells, where plasminogen activator inhibitors (e.g., PAI-1) may modulate their activities. Expression levels of these factors were compared in breast carcinomas relative to patient characteristics, carcinoma features, and clinical outcome. uPA, uPAR, and PAI-1 were quantified by enzyme-linked immunosorbent assay (ELISA) in extracts of 226 biopsies while estrogen receptor (ER) and progestin receptor (PR) were determined by enzyme immunoassay (EIA) or radio-ligand binding. Each set of assays contained a novel reference specimen with known quantities of each of these five analytes. Levels in ng/mg protein of these biomarkers exhibited ranges: uPA (0-12.3); uPAR (0-19.5); PAI-1 (0-91.2). When considered independently, expression of uPA, uPAR, or PAI-1 was unrelated to patient age or menopausal status. Although no correlation was observed between each analyte with stage, grade, or ER/PR status, levels appeared to differ with pathology and nodal status. A dendrogram from hierarchical clustering of uPA, uPAR, and PAI-1 levels in 106 specimens revealed three clusters of breast cancer patients. Kaplan-Meier analyses of uPA, uPAR, and PAI-1 indicated a correlation with overall survival (OS), suggesting collective examination of these biomarkers is useful in predicting clinical outcome of breast cancer. |
| | |
Authors:
|
Sarah A Andres; Angelena B Edwards; James L Wittliff |
Related Documents
:
|
23375374 - A comprehensive nuclear receptor network for breast cancer cells. 7397644 - A family with peutz-jeghers syndrome and bilateral breast cancer. 22583364 - Immunohistochemical verification of ductal differentiation in prostate cancer. 22757024 - Tu-c-213cd-10: shifting mlc to follow the prostate movements while concurrently treatin... 21641014 - Recent advances in the biology of merkel cell carcinoma. 23331404 - Clinical utility of the prostate cancer gene 3 (pca3) urine assay in japanese men under... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of clinical laboratory analysis Volume: 26 ISSN: 1098-2825 ISO Abbreviation: J. Clin. Lab. Anal. Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-04-02 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8801384 Medline TA: J Clin Lab Anal Country: United States |
Other Details:
|
Languages: eng Pagination: 93-103 Citation Subset: IM |
Copyright Information:
|
© 2012 Wiley-Liss, Inc. |
Affiliation:
|
Department of Biochemistry & Molecular Biology, Institute for Molecular Diversity & Drug Design, University of Louisville, Louisville, Kentucky. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Albuminuria, proteinuria, and urinary albumin to protein ratio in chronic kidney disease.
Next Document: RHD Allelic Identification Among D-Brazilian Blood Donors as a Routine Test Using Pools of DNA.